Company Overview and News

 
HCL Technologies faces key barrier ahead

2018-08-26 premium.thehindubusinessline
The stock of HCL Technologies is in a long-term uptrend. After a medium-term corrective decline, the stock took support at around ₹710 in early 2016 and resumed its uptrend that has been in place since 2009.
HCLTECH HCTHY 532281 VTUWY 533269 WABAG

 
VA Tech Wabag: Lacklustre Q1, no change in management outlook

2018-08-13 moneycontrol
VA Tech Wabag (VATW) is one of the world’s leading companies in the water treatment field. Its key competencies lie in design, completion and operation of drinking water and waste water treatment plants for both municipal and industrial sectors. After FY18 was marred by misses both in topline and order intake, the start of the new fiscal has been uninspiring.
VTUWY 533269 WABAG

 
VA Tech Wabag consolidated Q1 net up 39.7% to Rs 14.21 crore

2018-08-09 moneycontrol
Water treatment company VA Tech Wabag Ltd today said its consolidated net profit for April-June period grew by 39.7 percent to Rs 14.21 crore.
VTUWY 533269 WABAG

 
VA Tech Wabag Limited - Investor Presentation

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

 
VA Tech Wabag Limited - Outcome of Board Meeting

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

 
VA Tech Wabag Limited - Financial Result Updates

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

 
VA Tech Wabag Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

 
VA Tech Wabag Limited - Trading Plan under SEBI (PIT) Reg., 2015

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

 
VA Tech Wabag Limited - Shareholders meeting

2018-07-19 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

 
Va Tech WABAG board gives nod to raise funds

2018-07-09 moneycontrol
The Board of water treatment player VA Tech WABAG Ltd on Monday approved the proposal to raise funds through non-convertible debentures of up to Rs 300 crore.
VTUWY 533269 WABAG

 
VA Tech Wabag Limited - Outcome of Board Meeting

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
VTUWY 533269 WABAG

 
US-China trade war tensions to take centre stage in coming week; These 3 stocks to be in focus

2018-07-08 moneycontrol
The upcoming week will be important for the market as developments around imposition of US-China tariffs are likely to stay in focus through the week.
BAJAJ-AUTO KESORAMIND SHALPAINTS 532418 KTKBANK 532218 532977 SOUTHBANK 532187 INOXWIND HEROMOTOCO 500231 502937 INDUSINDBK VTUWY 533269 500182 532652 532210 ONP UMANGDAIR CUB HRTQY 539083 509874 KRIDF WABAG ANDHRABANK

 
Va Tech Wabag rises 3%, to consider fund raising on July 9

2018-07-05 moneycontrol
Shares of Va Tech Wabag gained more 3 percent in the opening trade on Thursday as company to consider fund raising on July 9.
VTUWY 533269 WABAG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...